An interventional study of Percutaneous Coronary Intervention (PCI) in Coronary Artery Disease, sponsored by Vastra Gotaland Region. Recruiting at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Vastra Gotaland Region · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 92 studies in Coronary Artery Disease with a site in Sweden — 14 open to participants now, 24 under way, 3 of them phase 3. Coronary Artery Disease · Sweden.
Among the 92 studies in Coronary Artery Disease with a site in Sweden, this one is the 37th largest by planned enrollment of the 71 interventional ones that give a count, is one of 4 that started in 2022, is one of 39 with no phase, reaches primary completion later than 15 of the 23 other live ones, and was the 76th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →14 of the 92 studies in Coronary Artery Disease with a site in Sweden are open now. Recruiting first, the newest first:
Vastra Gotaland Region · Sites in Sweden
Ages 18+
Uppsala University · Sites in Sweden
Ages 50–80
Region Skane · Sites in Sweden
Ages 40+ · Healthy volunteers
CSL Behring · Sites in Sweden, United States, Argentina and 32 more countries
Ages 18+
Region Östergötland · Sites in Sweden
Ages 18+
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
92 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 12 · Phase 3 13 · Phase 4 5
First in 1992; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 470 is above the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 500 across the 71 interventional studies, 1,356 across the 21 observational. Of the 62 that completed or were terminated, 22 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 92 have an industry lead sponsor. The 10 most frequent:
Vastra Gotaland Region is the lead sponsor of 276 studies on the registry; 110 are open to participants now.
Vastra Gotaland Region has 4 studies filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
2 of the studies in Coronary Artery Disease with a site in Sweden that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06578234Region SkaneHyperemic mYocardial Perfusion by adEnosine at diffeRent Doses | 2026-12-31 |
| NCT07884136Ribocure Pharmaceuticals ABRBD1119 in Coronary Artery Disease (CAD) | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 92 studies in Coronary Artery Disease with a site in Sweden, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The STICH-SWEDEHEART trial will compare PCI vs CABG for revascularization of patients with HF and LV systolic dysfunction (LV ejection fraction (LVEF) \<40%) and multi-vessel coronary artery disease.
Short background/ Rationale/Aim:
CABG has been shown to prolong survival in patients with reduced left ventricular (LV) function and multi-vessel coronary artery disease and "CABG is recommended as the first revascularization strategy choice in patients with multi-vessel disease and acceptable surgical risk". However, a major concern with CABG is the early risk of complications, including death and stroke. Although PCI has lower rates of peri-procedural complications than CABG in patients without heart failure (HF), this has not been confirmed in patients with HF. The lack of contemporary data comparing CABG and PCI in HF leaves clinicians with no guidance as to which option to choose, and a robust trial is therefore necessary. The STICH-SWEDEHEART trial will compare PCI vs CABG for revascularization of patients with HF and LV systolic dysfunction (LV ejection fraction (LVEF) \< 40%) and multi-vessel coronary artery disease.
Study objective:
To test whether PCI is non-inferior to CABG for revascularization of patients with ischemic heart failure.
Study design:
Multicentre, open-label, randomized controlled trial
Study population:
Patients with ischemic cardiomyopathy and reduced ejection fraction.
Number of subjects:
470 subjects
Investigational treatment:
PCI
Treatment in control group:
CABG
Study endpoints:
Primary endpoint (variable):
The occurrence of the composite of death, stroke, non-procedural myocardial infarction or heart failure hospitalization at 3 years.
Key secondary endpoint The hierarchical occurrence (in descending order of importance) at 3-year follow-up of time to death, time to stroke, time to non-procedural myocardial infarction, number of heart failure hospitalizations and 1-year Kansas City Cardiomyopathy Questionnaire (KCCQ) score; evaluated using the win ratio approach.
Secondary safety endpoints
In-hospital occurrence of the following:
The occurrence of in-hospital BARC ≥3 bleeding
Time to the occurrence of the following:
1. Time to the occurrence of the following: A. Death, stroke or non-procedural myocardial infarction B. Death or heart failure hospitalization C. Heart failure hospitalization D. Coronary revascularization E. Death or myocardial infarction F. Death or stroke 2. Total number of days in-hospital during index hospitalization 3. Total number of days in intensive care unit during index hospitalization 4. Quality of life at 30 days and 365 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will be revascularized by PCI
Procedure: Percutaneous Coronary Intervention (PCI)
Patients will be revascularized by CABG
Alternative treatment
Major adverse cardiac event
The occurrence of the composite of death, stroke, non-procedural myocardial infarction or heart failure hospitalization
Time frame: 3 years
The occurrence of death
Time to death
Time frame: 3 years
The occurrence of stroke
Time to stroke
Time frame: 3 year
The occurrence of non-procedural myocardial infarction,
Time to non-procedural myocardial infarction,
Time frame: 3 year
The occurrence of heart failure hospitalizations
Number of heart failure hospitalizations
Time frame: 3 year
Kansas City Cardiomyopathy Questionnaire (KCCQ) score
Kansas City Cardiomyopathy Questionnaire score; evaluated using the win ratio approach. High score mean a better outcome
Time frame: 1 year
Plan to share: Undecided
Started Sep 2022 (actual). Primary completion is estimated for Dec 2028, 75 months after the start.
Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 75 months is above that.
Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.